Since several other GPCRs implicated as oncogenic drivers in breast cancer, including the LPARs, CXCR4, and PAR1, have been shown to stimulate NF-κB via a CARMA3-dependent pathway, albeit in other contexts, we speculate that the C3BM signalosome may act as a central signaling node for multiple subsets of breast cancer characterized by overexpression and/or hyperactivity of these related GPCRs. The gene discussed is NFKB1; the disease is breast carcinoma.